Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page
- Check2 days agoChange DetectedAdded a 'Show glossary' option and updated footer notes to include 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', while removing the older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check9 days agoChange DetectedA reference to the 1994 NEJM randomized trial on preoperative chemotherapy plus surgery versus surgery alone in NSCLC was added to the page.SummaryDifference0.1%

- Check16 days agoChange DetectedRevision tag updated to v3.3.4, replacing the previous v3.3.3; this is an internal versioning update with no effect on study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check37 days agoChange DetectedFooter updated to show Revision: v3.3.3; HHS Vulnerability Disclosure and Revision: v3.3.2 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedAdded a background citation: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer (N Engl J Med 2012;366:2455-2465) to the study page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page shows a revision update from v3.3.1 to v3.3.2, a footer-level change that does not alter study details or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.